Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany

@article{Schdlich2005ModellingCE,
  title={Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany},
  author={Dr Peter K. Sch{\"a}dlich and Henning Zeidler and Angela Zink and Erika Gromnica-Ihle and Matthias Schneider and Christoph Straub and Josef Georg Brecht and Eduard Huppertz},
  journal={PharmacoEconomics},
  year={2005},
  volume={23},
  pages={395-420}
}
Objective: To estimate the 3-year incremental cost effectiveness and cost utility of introducing leflunomide into sequential therapy, consisting of the most frequently used disease-modifying antirheumatic drugs (DMARDs), for patients with rheumatoid arthritis in specialised, i.e. rheumatological, care in Germany. Design and setting: The analysis was conducted from the societal perspective in Germany using an existing 3-year simulation model, which was adapted to the German healthcare system… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Der Funktion - OMERCT - ILAR guideline for economic evaluations in rheu - sfragebogen Hannover ( FFbH ) : Ein Instrument zur matology

  • HH Raspe, U Hagedorn, T Kohlmann
  • Ann Rheum Dis
  • 2002

Similar Papers

Loading similar papers…